Jiangsu Vcare Pharmatech Co., Ltd. Selected as National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises
Published Time:
2024-09-09 17:47
Source:
Recently, the Ministry of Industry and Information Technology (MIIT) announced the sixth batch of National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises, andJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was successfully selected. Thisnational-levelhonor fully demonstrates that under its "dual-core business model," Jiangsu Vcare's scientific research capabilities, independent innovation capacity, market leadership, and future development potential have received official high recognition.
The National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises honor is specifically established to encourage small and medium-sized enterprises to achieve development in four aspects: specialized operations, refined output, unique processes, and novel products. It aims to cultivate a group of "pioneer" enterprises focused on niche markets with strong innovation capabilities, high market share, mastery of key core technologies, and excellent quality and efficiency, thereby strengthening the real economy—particularly manufacturing—and enhancing the stability and competitiveness of industrial and supply chains.
Since its establishment, Jiangsu Vcare has been committed to pharmaceutical R&D and innovation, adhering to the "Specialized, Refined, Unique, Innovative" development path, and building a full-chain chemical drug R&D service technology platform. From front-end research, the company has constructed integrated drug R&D platforms including AI molecular generation, drug screening, crystal/salt form selection, and novel drug formulation, establishing core innovation capabilities in early-stage product development. Back-end development further incorporates advanced manufacturing technology platforms such as synthetic biology, enzyme catalysis engineering, and continuous flow engineering, supplemented by preparation/separation technologies and multi-chiral drug development strategies, building robust technical barriers for industrialization. In 2024, the company's revenue will exceed RMB 400 million.
Jiangsu Vcare will continue to uphold its core values of"The better Care, The better Medicines", strengthen its core competitiveness and technological innovation capabilities, and contribute to Chinese pharmaceutical innovation through scientific, conceptual, and management innovation, thereby supporting the "Healthy China" initiative.
Related News
30
2024
/
12
On December 30, 2024, the first administration of VC005 tablets was completed in the Phase III clinical trial of oral treatment of moderate-to-severe atopic dermatitis (AD). VC005 is a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare). Positive top-line data were obtained from the unblinded Phase II clinical study of VC005 for AD, with primary endpoints showing superiority over the best drugs in the same class. Meanwhile, the overall safety and tolerability of the drug are good. In particular, the decreases in neutrophil and platelet counts caused by high dosage VC005 were smaller, compared with the positive control group of tofacitinib, and no significant reduction in lymphocyte count was observed.
View Details
18
2024
/
11
Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
View Details
01
2024
/
11
Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.
View Details
28
2024
/
10
Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"
Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.
View Details
23
2024
/
10
Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
View Details
22
2024
/
10
Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study
VC005 tablets, developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare), is a new-generation highly selective JAK1 inhibitor. The oral treatment of moderate-to-severe atopic dermatitis has initiated a Phase III clinical trial. It is a multicenter, randomized, double-blind, placebo parallel-controlled Phase III clinical study, aiming to evaluate the efficacy and safety of VC005 tablets for adult patients with moderate-to-severe atopic dermatitis. The trial is led by the Institute of Dermatology, Chinese Academy of Medical Sciences.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn